Yat Sun Or
2017
In 2017, Yat Sun Or earned a total compensation of $1.8M as Senior Vice President, Research & Development and Chief Scientific Officer at Enanta Pharmaceuticals, a 31% increase compared to previous year.
Compensation breakdown
| Bonus | $121,255 |
|---|---|
| Non-Equity Incentive Plan | $48,700 |
| Option Awards | $599,585 |
| Salary | $400,975 |
| Stock Awards | $574,369 |
| Other | $18,551 |
| Total | $1,763,435 |
Or received $599.6K in option awards, accounting for 34% of the total pay in 2017.
Or also received $121.3K in bonus, $48.7K in non-equity incentive plan, $401K in salary, $574.4K in stock awards and $18.6K in other compensation.
Rankings
In 2017, Yat Sun Or's compensation ranked 6,129th out of 14,666 executives tracked by ExecPay. In other words, Or earned more than 58.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,129 out of 14,666 | 58th |
Division Manufacturing | 2,252 out of 5,772 | 61st |
Major group Chemicals And Allied Products | 712 out of 2,075 | 66th |
Industry group Drugs | 549 out of 1,731 | 68th |
Industry Pharmaceutical Preparations | 431 out of 1,333 | 68th |
Source: SEC filing on January 19, 2018.
Or's colleagues
We found four more compensation records of executives who worked with Yat Sun Or at Enanta Pharmaceuticals in 2017.
News
Enanta Pharmaceuticals CEO Jay Luly's 2022 pay jumps 37% to $7.3M
January 20, 2023
Enanta Pharmaceuticals CEO Jay Luly's 2021 pay rises 2% to $5.3M
January 21, 2022
Enanta Pharmaceuticals CEO Jay Luly's 2020 pay rises 16% to $5.2M
January 21, 2021
Enanta Pharmaceuticals CEO Jay Luly's 2019 pay slips 1% to $4.5M
January 17, 2020
Enanta Pharmaceuticals CEO Jay Luly's 2018 pay rises 5% to $4.5M
January 18, 2019